Intra-aortic balloon pump

In January 2022, the Basque Office for Health Technology Assessment (OSTEBA) released an HTA report aiming to assess and compare the efficacy, effectiveness, and safety of the mechanical circulatory support devices most used in the healthcare setting for the treatment and prevention of cardiogenic shock, including Impella® devices, intra-aortic balloon pumps, and extracorporeal membrane oxygenation.

The report presents a summary of the reimbursement situation for the use of intra-aortic balloon pump (IABP) in cardiogenic shock in Europe. The following scenarios are considered: use of IABP for treatment of cardiogenic shock in unstable angina or acute myocardial infarction; use of IABP in high-risk PCI for unstable angina or acute myocardial infarction. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.